Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule inhibitor known as cFMS-IN-2, designed to target the macrophage colony-stimulating factor 1 receptor (CSF1R, also called c-Fms). It belongs to the class of organic compounds known as 2-furanilides and features a furan ring with cyano and carboxamide substituents linked to a substituted phenyl group. The primary mechanism of action is inhibition of CSF1R kinase activity, which plays a key role in regulating macrophage proliferation and survival. This makes it relevant for research into diseases involving macrophages or CSF1R signaling, such as certain cancers or inflammatory conditions. The compound has not been approved for clinical use and remains experimental[1][2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-cyano-furan-2-carboxylic acid [5-hydroxymethyl-2-(4-methyl-piperidin-1-yl)-phenyl]-amide.